Clinical trials in rare disease: challenges and opportunities
- PMID: 24014509
- PMCID: PMC3964003
- DOI: 10.1177/0883073813495959
Clinical trials in rare disease: challenges and opportunities
Abstract
The neuronal ceroid lipofuscinoses constitute one of many groups of rare childhood diseases for which disease-modifying treatments are nonexistent. Disease-specific barriers to therapeutic success include incomplete understanding of disease pathophysiology and limitations of treatments that cannot adequately cross the blood-brain barrier to access the central nervous system. Therapeutic development in the neuronal ceroid lipofuscinoses shares many challenges with other rare diseases, such as incomplete understanding of natural history to inform trial design, need for alternatives to the randomized controlled clinical trial, requirement for more sensitive outcome measures to quantify disease, limited access to resources required to mount a clinical trial (including funding), and difficulties of recruiting a small sample to participation. Solutions to these barriers will require multicenter collaboration, partnership with patient organizations, training a new generation of researchers interested in rare diseases, and leveraging existing resources.
Trial registration: ClinicalTrials.gov NCT01399047.
Keywords: Batten disease; clinical trials; lysosomal storage disease; neuronal ceroid lipofuscinosis; rare disease.
Similar articles
-
Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.Contemp Clin Trials. 2013 Jul;35(2):48-54. doi: 10.1016/j.cct.2013.04.004. Epub 2013 Apr 26. Contemp Clin Trials. 2013. PMID: 23628560 Free PMC article.
-
Funding resources for rare disease research.Biochim Biophys Acta. 2013 Nov;1832(11):1910-2. doi: 10.1016/j.bbadis.2013.04.016. Epub 2013 Apr 19. Biochim Biophys Acta. 2013. PMID: 23608548
-
A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an ultra-rare lysosomal storage disorder.Clin Trials. 2019 Oct;16(5):555-560. doi: 10.1177/1740774519855715. Epub 2019 Jun 11. Clin Trials. 2019. PMID: 31184505
-
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).Biochim Biophys Acta. 2013 Nov;1832(11):1906-9. doi: 10.1016/j.bbadis.2013.05.026. Epub 2013 Jun 6. Biochim Biophys Acta. 2013. PMID: 23747979 Free PMC article. Review.
-
Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis.Curr Opin Neurol. 2003 Apr;16(2):121-8. doi: 10.1097/01.wco.0000063762.15877.9b. Curr Opin Neurol. 2003. PMID: 12644737 Review.
Cited by
-
Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.Orphanet J Rare Dis. 2020 Sep 23;15(1):260. doi: 10.1186/s13023-020-01523-4. Orphanet J Rare Dis. 2020. PMID: 32967697 Free PMC article.
-
An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.JCO Precis Oncol. 2022 Jul;6:e2200019. doi: 10.1200/PO.22.00019. JCO Precis Oncol. 2022. PMID: 35939770 Free PMC article. Review.
-
Nirogacestat-the pathway to approval of the first treatment for desmoid tumors, a rare disease.Ther Adv Rare Dis. 2025 Feb 11;6:26330040251317546. doi: 10.1177/26330040251317546. eCollection 2025 Jan-Dec. Ther Adv Rare Dis. 2025. PMID: 39944188 Free PMC article. Review.
-
Retrospective assessment of clinical global impression of severity and change in GM1 gangliosidosis: a tool to score natural history data in rare disease cohorts.Orphanet J Rare Dis. 2025 Mar 14;20(1):125. doi: 10.1186/s13023-025-03614-6. Orphanet J Rare Dis. 2025. PMID: 40087722 Free PMC article.
-
Disease models for the development of therapies for lysosomal storage diseases.Ann N Y Acad Sci. 2016 May;1371(1):15-29. doi: 10.1111/nyas.13052. Epub 2016 May 4. Ann N Y Acad Sci. 2016. PMID: 27144735 Free PMC article. Review.
References
-
- Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2009;1793:697–709. - PubMed
-
- Kohlschutter A, Schulz A. Towards understanding the neuronal ceroid lipofuscinoses. Brain Dev. 2009;31:499–502. - PubMed
-
- Kousi M, Lehesjoki A-E, Mole SE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33:42–63. - PubMed
-
- The Neuronal Ceroid Lipofuscinoses (Batten Disease) 2nd Oxford University Press; New York: 2011. - PubMed
-
- Malcolm C, Hain R, Gibson F, et al. Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families. Acta Paediatr. 2012;101:985–992. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical